• Binding β2-Adrenergic Receptors by Capillary CEC

  2026-10-12

  The cited study evaluates an open-tubular capillary electrochromatography approach for estimating drug–β2-adrenergic receptor binding constants. Its results support analytical feasibility and agreement with prior affinity rankings, but they do not establish cellular signaling, clinical efficacy, or direct properties of epinephrine bitartrate.

• Apigenin: Promise and Limits in AD Research

  2026-10-12

  A 2025 network-medicine study identified Apigenin as a candidate for Alzheimer’s disease research, with neuroprotective effects reported across cellular models. The findings are hypothesis-generating rather than evidence of clinical efficacy, and separate oncology claims remain dependent on supplier-reported information in the supplied materials.

• Nitroaromatic Nannocystin Targets AKT1 in Colorectal Cancer

  2026-10-10

  Zhang and colleagues describe a nitroaromatic nannocystin that combines nanomolar anti-colorectal cancer activity with evidence of efficacy in patient-derived organoids and xenografts. The study links these effects, at least in part, to AKT1 through integrated transcriptomic, computational, and cellular target-engagement analyses, while leaving important questions about selectivity, pharmacology, and clinical translation unresolved.

• PX-478 2HCl: HIF-1α Research Context

  2026-10-09

  A source-grounded overview of PX-478 2HCl and HIF-1α research, comparing supplier-reported cancer and tumor-ischemia findings with a 2024 peer-reviewed study of cichoric acid in septic acute kidney injury. The article distinguishes evidence from interpretation, outlines conceptual applications, and defines key limitations without providing experimental procedures.

• Polybrene in Mutant p53 Research: Evidence and Limits

  2026-10-09

  This overview distinguishes the established research context for mutant p53 activation from the more limited, supplier-described role of Polybrene (Hexadimethrine Bromide) in delivery and assay workflows. It examines conceptual applications, reported findings from the TRAP-1 p53Y220C preprint, evidence strength, potential confounding factors, and the boundaries of what can reasonably be inferred about Polybrene in mutant-p53 studies.

• Cell Lysis Buffer in CAF–Prostate Cancer Research

  2026-10-08

  A source-grounded overview of how lysis reagents relate conceptually to Western blotting and immunoprecipitation in research on the CAF–ANGPTL4–IQGAP1 axis, with emphasis on published findings, evidence strength, product provenance, and study limitations.

• UTP Solution: From RNA Control to TRIM66 Insight

  2026-10-08

  A translational perspective on how defined UTP inputs can strengthen RNA-centered studies of TRIM66-dependent olfactory receptor regulation—without confusing a synthesis reagent with the epigenetic mechanism itself.

• Berberine Hydrochloride: Evidence and Research Scope

  2026-10-07

  Berberine hydrochloride is an isoquinoline alkaloid used to investigate AMPK signaling, LDL receptor regulation, lipid metabolism modulation, and cell-fate pathways. Evidence supports mechanistic and model-specific research applications, but findings from botanical extracts or preclinical systems should not be treated as proof of clinical efficacy.

• Verapamil HCl: From Calcium Blockade to Translation

  2026-10-07

  Verapamil HCl is more than an L-type calcium channel blocker: it is a translational probe that connects calcium signaling, drug transport, apoptosis, and inflammation while demanding careful interpretation of context-dependent evidence.

• Streptavidin-FITC for Glycan–Microbe Evidence

  2026-10-06

  Streptavidin-FITC can connect biotin-based fluorescence with questions about host glycosylation and microbial adhesion. This article interprets the ST3GAL1–Fusobacterium nucleatum findings through an evidence-centered framework rather than presenting another assay protocol.

• Protease Inhibitor Cocktail for OXPHOS Evidence

  2026-10-06

  A Protease Inhibitor Cocktail can strengthen the interpretability of protein-level OXPHOS studies without proving a biological mechanism by itself. This evidence-focused guide connects EDTA-free sample preservation with the reported LRPPRC–dasatinib findings and clarifies the boundaries between pre-analytical control and causal inference.

• VX-765 and Caspase-1: Evidence in Pyroptosis Research

  2026-10-05

  VX-765 is a research compound described as a prodrug of the active caspase-1 inhibitor VRT-043198. This overview examines its conceptual relevance to IL-1β and IL-18 signaling, pyroptosis, and the 2026 study of cordycepin combined with photodynamic therapy in breast cancer cells. It distinguishes supplier claims from peer-reviewed evidence, evaluates what pharmacological caspase-1 inhibition can and cannot demonstrate, and outlines key translational limitations without providing experimental procedures.

• Dorsomorphin (Compound C) in Translational Research

  2026-10-05

  Dorsomorphin (Compound C) offers a useful chemical lens on AMPK, BMP/Smad, autophagy, differentiation, and metabolic stress. This thought-leadership analysis places its reported activity alongside Nrf2 findings from progressive rotavirus infection while defining the validation boundaries required for translational interpretation.

• Intravesical p21 mRNA-LNP Therapy: Evidence and Limits

  2026-10-04

  A source-grounded overview of a 2026 FASEB Journal study investigating intravesical delivery of chemically modified p21 mRNA in lipid nanoparticles for bladder cancer. The article examines the biological rationale, preclinical findings, evidence strength, translational relevance, and limitations, including the absence of human data and head-to-head comparisons with established intravesical therapies.

• MAPK10–KRT16 Signaling in NSCLC Metastasis

  2026-10-03

  A 2026 study reports that MAPK10 suppresses non-small cell lung cancer metastasis by phosphorylating KRT16 and promoting RNF213-dependent ubiquitination and proteasomal degradation. The findings connect kinase signaling with cytoskeletal protein turnover, while the clinical and animal evidence still requires broader validation before the pathway can be considered a therapeutic or prognostic standard.

8544 records 1/570 page Next 12345 下5页 Last page